Imunon(US:IMNN) Globenewswire·2025-06-18 12:05Core Insights - IMUNON, Inc. is advancing its investigational gene-based immunotherapy IMNN-001 for the treatment of newly diagnosed advanced ovarian cancer, with positive translational data presented at the ESMO Gynaecological Cancers Congress 2025 [1][3] - The Phase 2 OVATION 2 Study demonstrated significant increases in key anti-cancer immune cytokines IL-12, IFN-γ, and TNF-α, indicating the localized effect of IMNN-001 in the tumor microenvironment [2][4] - The company is currently progressing to a Phase 3 pivotal trial (OVATION 3) following encouraging overall survival results from the OVATION 2 trial presented at ASCO 2025 [3][4] Company Overview - IMUNON is a clinical-stage biotechnology company focused on innovative treatments that utilize the body's natural mechanisms for effective responses against diseases [8] - The company's lead clinical program, IMNN-001, is a DNA-based immunotherapy designed to produce cancer-fighting molecules at the tumor site [9] - IMUNON's proprietary TheraPlas technology platform enables the delivery of cytokines and therapeutic proteins for solid tumors [6][9] Study Details - The Phase 2 OVATION 2 Study involved 112 participants receiving IMNN-001 in combination with standard-of-care chemotherapy, showing a favorable safety profile [2][4] - The study assessed the efficacy and biological activity of IMNN-001, with treatment leading to substantial increases in IL-12 levels by approximately 27-fold, IFN-γ by 62-fold, and TNF-α by 36-fold in the peritoneal cavity [2][4] - The study design included neoadjuvant and adjuvant chemotherapy followed by interval debulking surgery, aiming for optimal tumor removal [4] Industry Context - Epithelial ovarian cancer is a significant health concern, with approximately 20,000 new cases annually in the U.S., and a high risk of recurrence after treatment [7] - The need for effective therapies is underscored by poor five-year survival rates for patients diagnosed with advanced stages of the disease [7]